"The pharmaceutical sector is a highly regulated one and the exports are heavily guided by various regulatory regimes of the importing countries...," the Commerce and Industry Ministry said in a statement.
Citing statistics, the government said "The strong presence of Indian industry in the US and the reports of US FDA penalising Indian companies are only a small aberration."
The statement also assumed significance on a day there were reports from Brussels that European Union's anti-trust regulators may fine the domestic pharma company for allegedly blocking of entry of cheaper generic medicines in the market.
However, Ranbaxy Laboratories declined to comment on the reports.
More From This Section
The government statement said India has proven global quality standard capabilities as measured by number of Abbreviated New Drug Application (ANDA) approvals, DMF filings, USFDA/UK MHRA approved manufacturing facilities/bio equivalence centres, which are considered as key indicators for assessing the capabilities of any national pharma sector.
"This fact is further firmly demonstrated by the trends in the number of product approvals received from various major regulatory authorities of the world," it said.